Zobrazeno 31 - 40
of 40
pro vyhledávání: '"Cindy Delbrook"'
Autor:
David F. Stroncek, Crystal L. Mackall, Constance M. Yuan, Maryalice Stetler-Stevenson, James N. Kochenderfer, Hua Zhang, Bonnie Yates, Daniel W. Lee, Steven A. Rosenberg, Ling Zhang, Cindy Delbrook, Nirali N. Shah, Terry J. Fry
Publikováno v:
Blood. 126:684-684
CD19 chimeric antigen receptor (CAR) T cells have shown significant promise in multiple early phase trials including our own (Lancet 385:517-28). We manufacture CAR T cells containing CD28 and CD3z domains in 7 days using a retroviral platform. Sever
Autor:
Bonnie Yates, Terry J. Fry, Hua Zhang, Marianna Sabatino, Kimberly Lemberg, Thomas A. Fleisher, Crystal L. Mackall, Nirali N. Shah, Daniel W. Lee, Cindy Delbrook, Shakuntala Rampertaap, David F. Stroncek
Publikováno v:
Biology of Blood and Marrow Transplantation. 21:S309
Autor:
Ling Zhang, Maryalice Stetler-Stevenson, David F. Stroncek, Daniel W. Lee, Cindy Delbrook, Terry J. Fry, Marianna Sabatino, Alan S. Wayne, Steven R. Feldman, Yongzhi Cui, Nirali N. Shah, Crystal L. Mackall, Constance M. Yuan, Nick Tschernia, Hua Zhang, James N. Kochenderfer, Steven A. Rosenberg, Bonnie Yates
Publikováno v:
Blood. 124:381-381
Relapsed or refractory acute lymphoblastic leukemia (ALL) remains a difficult therapeutic challenge. We developed a platform where T cells are collected, transduced via retrovirus with a chimeric antigen receptor (CAR) targeting CD19 and incorporatin
Publikováno v:
Journal of Clinical Oncology. 32:10075-10075
10075 Background: Childhood melanoma is rare with an incidence of ~300 cases/yr in the United States. Stage IV disease is detected in 1-10% of reported pediatric melanomas. The treatment of this ch...
Autor:
Steven A. Rosenberg, James N. Kochenderfer, David F. Stroncek, Alan S. Wayne, Daniel W. Lee, Crystal L. Mackall, Nirali N. Shah, Maryalice Stetler-Stevenson, Cindy Delbrook, Marianna Sabatino, Kelly Richards
Publikováno v:
Blood. 122:68-68
Survival after relapsed and refractory pediatric pre-B ALL and non-Hodgkin lymphoma (NHL) is poor despite intensive chemotherapy and HSCT. CAR T cells combine the specificity and MHC independence of antibodies with the cytotoxic capacity of T cells.
Autor:
James N. Kochenderfer, Dave Stroncek, Daniel Warnell Lee, Marianna Sabatino, Alan S. Wayne, Steven A. Rosenberg, Nirali N. Shah, Kelly Richards, Maryalice Stetler-Stevenson, Crystal L. Mackall, Cindy Delbrook
Publikováno v:
Journal of Clinical Oncology. 31:10008-10008
10008 Background: Despite intensive chemotherapy and HSCT, outcomes in relapsed/refractory pediatric B cell ALL and NHL are poor. To treat children with or without prior allogeneic-HSCT and quickly deliver therapy, we developed a Phase I trial of 19C
Autor:
Marianna Sabatino, Alan S. Wayne, Steven A. Rosenberg, Cindy Delbrook, Daniel W. Lee, James N. Kochenderfer, Crystal L. Mackall, David F. Stroncek, Kelly Richards, Maryalice Stetler-Stevenson, Nirali N. Shah
Publikováno v:
Cancer Research. 73:LB-138
Introduction: Despite aggressive therapies such as HSCT, survival in relapsed and refractory pediatric ALL and NHL is poor. CAR modified T cells targeting CD19 have been effective in adult B-cell malignancies. These studies have employed T cells eith
Autor:
Marianna Sabatino, David F. Stroncek, Cindy Delbrook, Alan S. Wayne, Daniel W. Lee, Steven A. Rosenberg, Crystal L. Mackall, James N. Kochenderfer, Maryalice Stetler-Stevenson, Kelly Richards, Barbara Tumaini
Publikováno v:
Blood. 120:2609-2609
Abstract 2609 Children with relapsed or chemotherapy-refractory ALL have a poor prognosis despite the use of aggressive therapies such as HSCT. Chimeric antigen receptor modified T cells targeting the B-cell antigen CD19 have been reported to be effe
Autor:
Alan S. Wayne, Brigitte C. Widemann, Diane E. Cole, Melinda S. Merchant, Cindy Delbrook, Nirali N. Shah, Kelly Richards
Publikováno v:
Blood. 120:1497-1497
Abstract 1497 Background: Vincristine is active in many pediatric cancers, but cumulative neuromuscular toxicity is often dose limiting and requires a maximum dose cap. Liposomal carriers are capable of increasing the therapeutic index of anticancer
Autor:
David F. Stroncek, Kelly Richards, Alan S. Wayne, Kristin Baird, Crystal L. Mackall, David M. Loeb, Terry J. Fry, Cindy Delbrook, Nirali N. Shah, Hahn Khuu, Jason Levine, Mark Raffeld, Susan F. Leitman
Publikováno v:
Blood. 118:3055-3055
Abstract 3055 Background: Treatment of relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) remains challenging. The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other
- [1]
- « Předchozí
- 1
- 2
- 3
- 4